Taken together, our findings suggest that n-3 PUFAs may decrease the risk of breast cancers that arise in an immune microenvironment with low but not high CD8 T cell infiltration, while n-6 PUFAs may decrease breast cancer risk in an environment of high but not low CD8 infiltration. The gene discussed is CD8A; the disease is breast carcinoma.